Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.

about

Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.

Item

http://www.wikidata.org/entity/Q38701620

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Clinical aspects and perspecti ...... nts with biliary tract cancer.

@en

type

Item

label

Clinical aspects and perspecti ...... nts with biliary tract cancer.

@en

prefLabel

Clinical aspects and perspecti ...... nts with biliary tract cancer.

@en

P1476

Clinical aspects and perspecti ...... ents with biliary tract cancer

@en

P2093

Lars Henrik Jensen

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Targeted Therapy in Biliary Tract Cancers

Cholangiocarcinoma

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.

Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Shared decision making in clinical medicine: past research and future directions.

P304

359-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2016.1142973

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lars Henrik Jensen

P577

2016-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26781267

http://www.w3.org/2001/XMLSchema#string